Based on the IMpower010 results, atezolizumab was approved by Health Canada in 2022 as a monotherapy for adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adults with stage II-IIIA NSCLC (Union for International Cancer Control/American Joint Committee on Cancer Staging Manual, 7th edition) with tumors with PD-L1 expression on ≥50% of tumor cells (PD-L1 high) [14]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.